• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Acurx Pharmaceuticals Inc.

    2/14/23 11:59:03 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACXP alert in real time by email
    SC 13G 1 armistice-ards123122.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*



    Aridis Pharmaceuticals, Inc.

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    040334104

    (CUSIP Number)

     

     

    December 31, 2022
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  040334104
     SCHEDULE 13G
    Page 2 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Armistice Capital, LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    2,997,111
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    2,997,111
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,997,111
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.99%
    12
    TYPE OF REPORTING PERSON
     
    IA, OO

     


     

    CUSIP No.  040334104
     SCHEDULE 13G
    Page 3 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Steven Boyd
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States of America
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    2,997,111
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    2,997,111
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,997,111
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.99%
    12
    TYPE OF REPORTING PERSON
     
    IN, HC

     


     

     

    CUSIP No. 040334104
     SCHEDULE 13G
    Page 4 of 8 Pages

     

    Item 1.(a) Name of Issuer

    Aridis Pharmaceuticals, Inc.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    983 University Avenue, Bldg. B

    Los Gatos, California 95032

    Item 2.(a) Names of Person Filing:

    Armistice Capital, LLC

    Steven Boyd

    Collectively, the "Reporting Persons"

      

    Item 2.(b) Address of Principal Business Office:

     

    Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

     

    Steven Boyd

    c/o Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

      

    Item 2.(c) Citizenship:

     

    Armistice Capital, LLC - Delaware

    Steven Boyd - United States of America

      

    Item 2.(d) Title of Class of Securities

     

    Common Stock (“Shares”)

     

    Item 2.(e) CUSIP No.:

    040334104

     

    CUSIP No.  040334104
     SCHEDULE 13G
    Page 5 of 8 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) x A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

    CUSIP No. 040334104
     SCHEDULE 13G
    Page 6 of 8 Pages

     

     

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount beneficially owned as of December 31, 2022:

    Armistice Capital, LLC - 2,997,111

    Steven Boyd - 2,997,111 

    (b) Percent of Class as of December 31, 2022:

    Armistice Capital, LLC - 9.99%

    Steven Boyd - 9.99% 

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote

    Armistice Capital, LLC - 0

    Steven Boyd - 0 

    (ii) Shared power to vote or to direct the vote

    Armistice Capital, LLC - 2,997,111

    Steven Boyd - 2,997,111 

    (iii) Sole power to dispose or to direct the disposition of

    Armistice Capital, LLC - 0

    Steven Boyd - 0 

    (iv) Shared power to dispose or to direct the disposition of

    Armistice Capital, LLC - 2,997,111

    Steven Boyd - 2,997,111

    The percentage of Shares reported to be beneficially owned by the Reporting Persons are based on 30,001,119 Shares outstanding as of December 15, 2022, as reported on the Issuer’s Form 424B3 filed with the Securities and Exchange Commission on December 15, 2022.

    Armistice Capital, LLC ("Armistice Capital") is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

     

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 040334104
     SCHEDULE 13G
    Page 7 of 8 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2023

     

     

     

     

    Armistice Capital, LLC

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

    Managing Member

           

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

           

     

     
    CUSIP No. 040334104
     SCHEDULE 13G
    Page 8 of 8 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: February 14, 2023

     

     

    Armistice Capital, LLC

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

    Managing Member

           
     

     
      By:  /s/ Steven Boyd
       

    Steven Boyd

           
    Get the next $ACXP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACXP

    DatePrice TargetRatingAnalyst
    11/29/2021$12.00Buy
    Maxim Group
    More analyst ratings

    $ACXP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update

      STATEN ISLAND, N.Y., May 13, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the first quarter ended March 31, 2025.   Highlights of the first quarter ended March 31, 2025, or in some cases shortly thereafter, include: In January 2025, the Company announced it had closed a $2.5 million registered direct offering priced at the market under Nasdaq rules.Also in January 2025, we announced that we received positive regulatory guidance from the European Medicines Agency (E

      5/13/25 7:01:00 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acurx Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 13, 2025 Conference Call and Provide Business Update

      STATEN ISLAND, N.Y., April 30, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its first quarter 2025 financial results on Tuesday, May 13, 2025 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows: Date: Tuesday, May 13, 2025 Time: 8:00 a.m. ET Toll free (U.S.): 1-877-790-1503; Conference

      4/30/25 7:30:00 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase

      STATEN ISLAND, N.Y., April 28, 2025 /PRNewswire/ -- Acurx Pharmaceuticals (NASDAQ:ACXP) (Acurx or the Company), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections today announced that David P. Luci, President & Chief Executive Officer, will participate virtually in a fireside chat at A.G.P.'s Healthcare Company Showcase on Wednesday, May 21, 2025, at 9:00 a.m. ET. The Company's lead antibiotic candidate, ibezapolstat (IBZ), is ready to advance to international Phase 3 clinical trials for treatment of patients with C. difficile infection (CDI). A live webcast of the presentation can be found here. A replay o

      4/28/25 7:30:00 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACXP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Acurx Pharmaceuticals with a new price target

      Maxim Group initiated coverage of Acurx Pharmaceuticals with a rating of Buy and set a new price target of $12.00

      11/29/21 8:33:36 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACXP
    SEC Filings

    See more
    • SEC Form S-1 filed by Acurx Pharmaceuticals Inc.

      S-1 - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

      5/21/25 4:16:04 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form D filed by Acurx Pharmaceuticals Inc.

      D - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

      5/20/25 3:32:14 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Acurx Pharmaceuticals Inc.

      PRE 14A - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

      5/19/25 4:05:41 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACXP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Shawah Robert G.

      4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

      2/6/25 5:47:58 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by President and CEO Luci David P

      4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

      2/6/25 5:46:58 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Deluccia Robert J

      4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

      2/6/25 5:45:47 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACXP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Acurx Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Acurx Pharmaceuticals, Inc. (0001736243) (Subject)

      2/14/24 2:39:21 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Acurx Pharmaceuticals Inc.

      SC 13G - Acurx Pharmaceuticals, Inc. (0001736243) (Subject)

      2/14/23 11:59:03 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Acurx Pharmaceuticals Inc.

      SC 13G - Acurx Pharmaceuticals, Inc. (0001736243) (Subject)

      2/14/23 11:52:45 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACXP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Scodari Joseph C bought $25,000 worth of shares (24,631 units at $1.01), increasing direct ownership by 800% to 27,708 units (SEC Form 4)

      4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

      1/8/25 4:32:30 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Sailer Carl bought $25,000 worth of shares (24,631 units at $1.01), increasing direct ownership by 22% to 137,183 units (SEC Form 4)

      4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

      1/8/25 4:31:59 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Luci David P bought $50,000 worth of shares (49,261 units at $1.01), increasing direct ownership by 5% to 1,097,458 units (SEC Form 4)

      4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

      1/8/25 4:31:33 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACXP
    Financials

    Live finance-specific insights

    See more
    • Acurx Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 13, 2025 Conference Call and Provide Business Update

      STATEN ISLAND, N.Y., April 30, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its first quarter 2025 financial results on Tuesday, May 13, 2025 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows: Date: Tuesday, May 13, 2025 Time: 8:00 a.m. ET Toll free (U.S.): 1-877-790-1503; Conference

      4/30/25 7:30:00 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on March 18, 2025 Conference Call and Provide Business Update

      STATEN ISLAND, N.Y., Feb. 28, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its fourth quarter and full year 2024 financial results on Tuesday, March 18, 2025 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows: Date: Tuesday, March 18, 2025 Time: 8:00 a.m. ET Toll free (U.S.): 1-877-79

      2/28/25 8:00:00 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update

      STATEN ISLAND, N.Y., Nov. 13, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the third quarter ended September 30, 2024. Highlights of the third quarter ended September 30, 2024, or in some cases shortly thereafter, include: In July 2024, results from the ibezapolstat (IBZ) Phase 2 clinical trial in patients with C. difficile Infection (CDI) were presented at the 17th Biennial Congress of the Anaerobe Society of the Americas by Taryn A. Eubank, PharmD, BCIDP,

      11/13/24 7:00:00 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care